Vaccines

Infectious Diseases & Vaccines

It is our job to help Sponsors determine the safety and effectiveness of their vaccines, and we commit our full array of resources to the accomplishment of that goal in every study.

Through years of CRO and SMO experience in large-scale clinical trials, we have developed the systems, processes, and training mechanisms to provide innovative and efficient services from the design to completion of your vaccine clinical trial.

Meet our scientific leader for vaccine trials

Our leader for vaccines is Prof. dr. Louis Bont, paediatric infectious disease specialist at the University Medical Centre Utrecht, the Netherlands. He is the leader of several groups, and an international principal investigator for many vaccine studies. He is involved in the Dutch RSV Neonatal Network, and ESPID Research Committee.

The Primary Care Research Network (PCRN) is our proprietary network of hundreds of general practitioners, pharmacists, and practice assistants who specialize in clinical drug research in a primary care setting. PCRN provides smart clinical trial design and oversight, industry-leading recruitment and retention, and peerless data quality and operational execution.

Read more

We also founded Africa Clinical, another proprietary site network providing access to sub-Saharan African regions. This network provides rapid participant recruitment and high retention. Africa Clinical consists of 40 local investigators from 20 countries at over 100 sites.

Read more

We established ReSViNET in 2014, and since 2018, ReSViNET has been a foundation — a financially and otherwise independent regulated entity. Julius Clinical works closely with ReSViNET to provide operational support to RSV clinical trials and observational studies. Our operational team has extensive experience in coordinating these studies, and ReSViNET has access to sites in countries across the globe, providing fast recruitment and high retention rates.

Read more

Julius Clinical has deep expertise in a broad range of vaccine clinical trials — including maternal vaccines — and we can even serve as the main investigational site for your vaccine study.

An example of our infectious disease trial capabilities is a completed influenza vaccine study that has been conducted at UMC Utrecht. We enrolled 2,100 participants aged 60+ to test a higher dose of an existing flu vaccine in a healthy population.

Our expert vaccine clinical trials team

Our team of operational experts has conducted years of important research on a massive scale, including the largest vaccine study ever done, consisting of approximately 84,000 participants.

Image of Leyla Kragten-Tabatabaie
Image of Dr. David Ong
Image of Jochem Hogenhuis

Related webinars

Webinar: Progress in RSV Vaccines and Monoclonal Antibodies
  • Webinars
  • Infectious Diseases & Vaccines, RSV, Vaccines

Webinar: Progress in RSV Vaccines and Monoclonal Antibodies

On May 10, our partner ReSViNET presented the webinar: Progress in RSV Vaccines and Monoclonal AntibodiesIn this webinar, Professor Barney Graham, MD, PhD, shared his views on the lanscape of RSV therapeutics. The webinar was hosted by Prof. D...

COVID-19 lessons from pandemic to endemic
  • Webinars
  • Infectious Diseases & Vaccines, Vaccines

COVID-19 lessons from pandemic to endemic

We presented the webinar COVID-19 lessons from pandemic to endemic. During this webinar Prof. Jerome H. Kim, Director General of the International Vaccine Institute (IVI), discussed:- Pandemic preparedness – lessons learned - Clinical Devel...

Speakers: Leyla Kragten-Tabatabaie
More webinars

Vaccine trial resources

Explore our vaccine clinical trial capabilities, case studies, and other resources.

Download

"*" indicates required fields

*
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Request for proposal

"*" indicates required fields

*
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
This field is for validation purposes and should be left unchanged.

Share

Twitter Facebook LinkedIn